Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Oct 7;27:187–199. doi: 10.1016/j.ebiom.2017.10.007

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2017 The Authors

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

PMC Copyright notice

Fig. 5 — Identifying PFIC1 patients using phenotypic and morphological characteristic of M2c from patients with normal-GGT PFIC.

HPBMo were prepared from patients with normal-GGT PFIC. The obtained HPBMo were seeded, differentiated into HMDM by culture for 4 to 10 days in RPMI/M-CSF, and then cultured for 6 days in RPMI/M-CSF with IL-10 (40 ng/ml) to elicit polarization into M2c. The IL-10-treated HMDM were stained with fluorochrome-labeled antibodies against CD163 and CD14, subjected to flow cytometry, and the results were analyzed as described in Fig. 2c using FlowJo software (v. 10). Seven independent experiments were performed to analyze 12 patients (n = 4 PFIC1 patients; n = 4 PFIC2 and PFIC2-like patients; n = 4 PFIC1-like patients). In each experiment, HPBMo from more than three age-matched control subjects were pooled to minimize interindividual variability and employed as control cells. (a, b) Phenotypic and morphological differences in IL-10-treated HMDM of PFIC1 patients from patients with other PFIC subtypes. Graphs show cell surface expression of CD163 and CD14, and SSC of IL-10-treated HMDM on the horizontal axis (a) (control subjects, blue line; PFIC1 patient no.4, red filled line; PFIC2 patient no.2, green line; isotype control, black line). A representative result of four PFIC1 patients and four PFIC2 and PFIC2-like disease patients is shown. The MFI of CD163 and CD14 and the mean value of SSC in the cells from each patient with PFIC1, PFIC2, and PFIC2-like disease were determined and expressed relative to those of the cells from age-matched control subjects analyzed simultaneously (b). Each bar represents mean ± standard deviation (n = 4 PFIC1 patients; n = 4 PFIC2 and PFIC2-like patients). *, P < 0.05; **, P < 0.01. (c, d) Discrimination of patients with PFIC1 from patients with PFIC1-like disease. Graphs in (c) show cell surface expression of CD163 and CD14, and SSC of IL-10-treated HMDM on the horizontal axis (control subjects, blue line; PFIC1-like patients, red filled line). Each patient with PFIC1-like disease was analyzed in independent experiments. Their mean values were quantified as relative to those of the cells from the age-matched control subjects in each experiment and are plotted on a radar chart (d) (control subjects, blue line; PFIC1-like patients, red line; PFIC1 patients, green line). Data for PFIC1 patients are those shown in (b).